Variantyx – a leader in genomic precision medicine – recently announced that it has secured additional funding from its portfolio of investors, which includes Robert Bosch Venture Capital, Pitango HealthTech, New Era Capital Partners, 20/20 HealthCare Partners, and Peregrine Ventures.
The company is a provider of advanced genomic testing for genetic disorders, reproductive health, and precision oncology markets, continues to add many of the largest US healthcare systems to its customer base, and rapidly growing its market share.
The additional funding round, which brings the total amount invested in Variantyx to over $120 million, will drive commercial expansion, enabling the company to build significant economic value and bring the power of precision medicine to larger numbers of patients at an accelerated rate.
KEY QUOTES:
“This funding demonstrates continued trust and confidence in our ability to deliver on the long term goals of the company. As we further expand our commercial footprint we have the opportunity to bring real improvements in patient outcomes to an increasingly larger subset of the population due to our unmatched diagnostic capabilities and improved personalized treatment recommendations while growing value for shareholders.”
— Haim Neerman, CEO of Variantyx
“Variantyx is fundamentally changing molecular diagnostics. With a portfolio of disruptive products enabled by its whole genome analysis platforms and strong unit economics, the company is making a huge difference in the diagnostic and treatment markets.”
— David Margulies, MD, Variantyx’s Chairman of the Board
